Get the Stockscreener App
70.69
1.05%
-0.75
After Hours:
71.00
0.31
+0.44%
Biomarin Pharmaceutical Inc stock is traded at $70.69, with a volume of 1.65M.
It is down -1.05% in the last 24 hours and down -0.66% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
See More
Previous Close:
$71.44
Open:
$70.61
24h Volume:
1.65M
Relative Volume:
1.15
Market Cap:
$13.53B
Revenue:
$2.75B
Net Income/Loss:
$322.29M
P/E Ratio:
42.33
EPS:
1.67
Net Cash Flow:
$300.88M
1W Performance:
-1.81%
1M Performance:
-0.66%
6M Performance:
+0.57%
1Y Performance:
-19.06%
1-Day Range:
$69.05
$71.28
1-Week Range:
$69.05
$73.18
52-Week Range:
$60.63
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
70.69 | 13.53B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
US FDA approves Sanofi's bleeding disorder therapy - MarketScreener
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance
Is BioMarin Pharmaceutical Inc. (BMRN) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharm - GuruFocus
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) - Yahoo Finance
BioMarin pharmaceutical CAO Erin Burkhart sells $92,618 in stock By Investing.com - Investing.com Australia
BioMarin pharmaceutical CAO Erin Burkhart sells $92,618 in stock - Investing.com India
Citi maintains Neutral on BioMarin stock, price target at $82 - Investing.com
BioMarin Pharmaceutical (BMRN): Among Paul Singer’s Latest Portfolio’s Top Stock Picks - Insider Monkey
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) - PR Newswire
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now? - Yahoo Finance
Is BioMarin Pharmaceutical (BMRN) the Best Biotech Stock According to Billionaires? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why - TradingView
Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to Trade - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
544 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by SBI Securities Co. Ltd. - Defense World
Smartleaf Asset Management LLC Increases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
4 Discounted PEG Stocks Offering the Best Returns to Value Investors - Yahoo Finance
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at StockNews.com - Defense World
BioMarin Pharmaceutical Inc. to Host Earnings Call - ACCESS Newswire
Proficio Capital Partners LLC Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin at TD Cowen Conference: Strategic Growth and Innovation - Investing.com
First Week of October 17th Options Trading For BioMarin Pharmaceutical (BMRN) - Nasdaq
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
Phenylketonuria Treatment Market Projected To Witness Substantial Growth, 2025-2032: BioMarin Pharmaceutical - EIN News
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Analysts - Defense World
The Strong Earnings Posted By BioMarin Pharmaceutical (NASDAQ:BMRN) Are A Good Indication Of The Strength Of The Business - Simply Wall St
Statutory Profit Doesn't Reflect How Good BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings Are - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Sanctuary Advisors LLC - Defense World
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position Lessened by Handelsbanken Fonder AB - MarketBeat
Los Angeles Capital Management LLC Purchases 28,431 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BMRN or CSLLY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance Australia
New York State Common Retirement Fund Has $6.16 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Cantor Fitzgerald Has Positive View of BMRN FY2025 Earnings - MarketBeat
Oppenheimer Upgrades BioMarin Pharmaceutical (NASDAQ:BMRN) to "Outperform" - MarketBeat
Investor Network: BioMarin Pharmaceutical Inc. to Host Earnings Call - ACCESS Newswire
Q2 Earnings Estimate for BMRN Issued By Leerink Partnrs - MarketBeat
Research Analysts Set Expectations for BMRN Q1 Earnings - MarketBeat
Global Retirement Partners LLC Increases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
BioMarin Pharmaceutical earnings rise 16% in Q4 - North Bay Business Journal
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CAO Erin Burkhart Sells 1,344 Shares - MarketBeat
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.18%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):